Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia

Cell Reports

Volumn 11, Issue 9, 2015, Pages 1446-1457

  Sujobert, Pierre ^a,b,c   Poulain, Laury ^a,b,c   Paubelle, Etienne ^d,e,f,g   Zylbersztejn, Florence ^d,e,f,g   Grenier, Adrien ^a,b,c   Lambert, Mireille ^a,b,c   Townsend, Elizabeth C ^h   Brusq, Jean Marie ⁱ   Nicodeme, Edwige ⁱ   Decrooqc, Justine ^d,e,f,g   Nepstad, Ina ^j   Green, Alexa S ^a,b,c   Mondesir, Johanna ^a,b,c   Hospital, Marie Anne ^a,b,c   Jacque, Nathalie ^a,b,c   Christodoulou, Alexandra ^h   Desouza, Tiffany A ^h   Hermine, Olivier ^d,e,f,g   Foretz, Marc ^a,b,g   Viollet, Benoit ^a,b,g   Lacombe, Catherine ^a,b,c   Mayeux, Patrick ^a,b,c   Weinstock, David M ^h   Moura, Ivan C ^d,e,f,g   Bouscary, Didier ^a,b,c   Tamburini, Jerome ^a,b,c   more..

^a INSTITUT COCHIN   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Equipe Labellisée Par la Ligue Nationale Contre le Cancer 20112013   (France)

^d INSERM   (France)

^e PARIS DESCARTES SORBONNE PARIS CITÉ UNIVERSITY   (France)

^f CNRS   (France)

^g Laboratory of Excellence GR Ex   (France)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ GLAXOSMITHKLINE   (France)

^j HAUKELAND UNIVERSITY HOSPITAL   (Norway)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; GSK 621; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ACTIVATOR; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; TUBERIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GSK621; IMIDAZOLE DERIVATIVE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PYRIMIDINONE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ANIMAL CELL; APOPTOSIS; ARTICLE; AUTOPHAGY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; CYTOTOXICITY; ENZYME ACTIVATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LETHALITY; MIDDLE AGED; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VERY ELDERLY; AGONISTS; ANIMAL; DNA MICROARRAY; DRUG EFFECTS; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; NUDE MOUSE; POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSMISSION ELECTRON MICROSCOPY; XENOGRAFT;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME ACTIVATION; FLUORESCENT ANTIBODY TECHNIQUE; HETEROGRAFTS; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, NUDE; MICROSCOPY, ELECTRON, TRANSMISSION; MULTIPROTEIN COMPLEXES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; PYRIMIDINONES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84930762848     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.04.063     Document Type: Article

References (52)

1. Amadori S., Stasi R., Martelli A.M., Venditti A., Meloni G., Pane F., Martinelli G., Lunghi M., Pagano L., Cilloni D., et al. Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107). Br. J. Haematol. 2012, 156:205-212.
2. Atkins C., Liu Q., Minthorn E., Zhang S.Y., Figueroa D.J., Moss K., Stanley T.B., Sanders B., Goetz A., Gaul N., et al. Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 2013, 73:1993-2002.
3. Babcock J.T., Nguyen H.B., He Y., Hendricks J.W., Wek R.C., Quilliam L.A. Mammalian target of rapamycin complex 1 (mTORC1) enhances bortezomib-induced death in tuberous sclerosis complex (TSC)-null cells by a c-MYC-dependent induction of the unfolded protein response. J. Biol. Chem. 2013, 288:15687-15698.
4. Barabé F., Kennedy J.A., Hope K.J., Dick J.E. Modeling the initiation and progression of human acute leukemia in mice. Science 2007, 316:600-604.
5. Büchner T., Schlenk R.F., Schaich M., Döhner K., Krahl R., Krauter J., Heil G., Krug U., Sauerland M.C., Heinecke A., et al. Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm-combined prospective analysis by the German AML Intergroup. J. Clin. Oncol. 2012, 30:3604-3610.
6. Budovskaya Y.V., Stephan J.S., Reggiori F., Klionsky D.J., Herman P.K. The Ras/cAMP-dependent protein kinase signaling pathway regulates an early step of the autophagy process in Saccharomyces cerevisiae. J. Biol. Chem. 2004, 279:20663-20671.
7. Calvisi D.F., Wang C., Ho C., Ladu S., Lee S.A., Mattu S., Destefanis G., Delogu S., Zimmermann A., Ericsson J., et al. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology 2011, 140:1071-1083.
8. Campeau E., Ruhl V.E., Rodier F., Smith C.L., Rahmberg B.L., Fuss J.O., Campisi J., Yaswen P., Cooper P.K., Kaufman P.D. A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS ONE 2009, 4:e6529.
9. Clarke H.J., Chambers J.E., Liniker E., Marciniak S.J. Endoplasmic reticulum stress in malignancy. Cancer Cell 2014, 25:563-573.
10. Cool B., Zinker B., Chiou W., Kifle L., Cao N., Perham M., Dickinson R., Adler A., Gagne G., Iyengar R., et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab. 2006, 3:403-416.
11. Egan D.F., Shackelford D.B., Mihaylova M.M., Gelino S., Kohnz R.A., Mair W., Vasquez D.S., Joshi A., Gwinn D.M., Taylor R., et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 2011, 331:456-461.
12. Elgendy M., Sheridan C., Brumatti G., Martin S.J. Oncogenic Ras-induced expression of Noxa and Beclin-1 promotes autophagic cell death and limits clonogenic survival. Mol. Cell 2011, 42:23-35.
13. Faubert B., Boily G., Izreig S., Griss T., Samborska B., Dong Z., Dupuy F., Chambers C., Fuerth B.J., Viollet B., et al. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab. 2013, 17:113-124.
14. Fullerton M.D., Galic S., Marcinko K., Sikkema S., Pulinilkunnil T., Chen Z.P., O'Neill H.M., Ford R.J., Palanivel R., O'Brien M., et al. Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat. Med. 2013, 19:1649-1654.
15. Gan B., Hu J., Jiang S., Liu Y., Sahin E., Zhuang L., Fletcher-Sananikone E., Colla S., Wang Y.A., Chin L., Depinho R.A. Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells. Nature 2010, 468:701-704.
16. Green A.S., Chapuis N., Maciel T.T., Willems L., Lambert M., Arnoult C., Boyer O., Bardet V., Park S., Foretz M., et al. The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood 2010, 116:4262-4273.
17. Gurumurthy S., Xie S.Z., Alagesan B., Kim J., Yusuf R.Z., Saez B., Tzatsos A., Ozsolak F., Milos P., Ferrari F., et al. The Lkb1 metabolic sensor maintains haematopoietic stem cell survival. Nature 2010, 468:659-663.
18. Gwinn D.M., Shackelford D.B., Egan D.F., Mihaylova M.M., Mery A., Vasquez D.S., Turk B.E., Shaw R.J. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 2008, 30:214-226.
19. Hardie D.G., Ross F.A., Hawley S.A. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 2012, 13:251-262.
20. Harding H.P., Zhang Y., Scheuner D., Chen J.J., Kaufman R.J., Ron D. Ppp1r15 gene knockout reveals an essential role for translation initiation factor 2 alpha (eIF2alpha) dephosphorylation in mammalian development. Proc. Natl. Acad. Sci. USA 2009, 106:1832-1837.
21. Inoki K., Li Y., Zhu T., Wu J., Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 2002, 4:648-657.
22. Inoki K., Zhu T., Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003, 115:577-590.
23. Jeon S.M., Chandel N.S., Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 2012, 485:661-665.
24. Kamentsky L., Jones T.R., Fraser A., Bray M.A., Logan D.J., Madden K.L., Ljosa V., Rueden C., Eliceiri K.W., Carpenter A.E. Improved structure, function and compatibility for CellProfiler: modular high-throughput image analysis software. Bioinformatics 2011, 27:1179-1180.
25. Kelsey I., Manning B.D. mTORC1 status dictates tumor response to targeted therapeutics. Sci. Signal. 2013, 6:pe31.
26. Kharas M.G., Okabe R., Ganis J.J., Gozo M., Khandan T., Paktinat M., Gilliland D.G., Gritsman K. Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. Blood 2010, 115:1406-1415.
27. Kim J., Kundu M., Viollet B., Guan K.L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell Biol. 2011, 13:132-141.
28. Laderoute K.R., Amin K., Calaoagan J.M., Knapp M., Le T., Orduna J., Foretz M., Viollet B. 5'-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. Mol. Cell. Biol. 2006, 26:5336-5347.
29. Lamb C.A., Yoshimori T., Tooze S.A. The autophagosome: origins unknown, biogenesis complex. Nat. Rev. Mol. Cell Biol. 2013, 14:759-774.
30. Levine B., Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008, 132:27-42.
31. Liu X., Chhipa R.R., Pooya S., Wortman M., Yachyshin S., Chow L.M., Kumar A., Zhou X., Sun Y., Quinn B., et al. Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK. Proc. Natl. Acad. Sci. USA 2014, 111:E435-E444.
32. Mirguet, O., and Bouillot, A. (2011). Patent WO 2011138307A1 Pyrrolo [3, 2 -d] pyrimidin-3 -yl derivatives used as activators of ampk. http://www.google.com.na/patents/WO2011138307A1?cl=de.
33. Mizuki M., Fenski R., Halfter H., Matsumura I., Schmidt R., Müller C., Grüning W., Kratz-Albers K., Serve S., Steur C., et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 2000, 96:3907-3914.
34. Mizushima N., Yoshimori T., Levine B. Methods in mammalian autophagy research. Cell 2010, 140:313-326.
35. Nakada D., Saunders T.L., Morrison S.J. Lkb1 regulates cell cycle and energy metabolism in haematopoietic stem cells. Nature 2010, 468:653-658.
36. Ozcan U., Yilmaz E., Ozcan L., Furuhashi M., Vaillancourt E., Smith R.O., Görgün C.Z., Hotamisligil G.S. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006, 313:1137-1140.
37. Ozcan U., Ozcan L., Yilmaz E., Düvel K., Sahin M., Manning B.D., Hotamisligil G.S. Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol. Cell 2008, 29:541-551.
38. Perl A.E., Kasner M.T., Tsai D.E., Vogl D.T., Loren A.W., Schuster S.J., Porter D.L., Stadtmauer E.A., Goldstein S.C., Frey N.V., et al. A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin. Cancer Res. 2009, 15:6732-6739.
39. Scotland S., Saland E., Skuli N., de Toni F., Boutzen H., Micklow E., Sénégas I., Peyraud R., Peyriga L., Théodoro F., et al. Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells. Leukemia 2013, 27:2129-2138.
40. Shackelford D.B., Vasquez D.S., Corbeil J., Wu S., Leblanc M., Wu C.L., Vera D.R., Shaw R.J. mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc. Natl. Acad. Sci. USA 2009, 106:11137-11142.
41. Shackelford D.B., Abt E., Gerken L., Vasquez D.S., Seki A., Leblanc M., Wei L., Fishbein M.C., Czernin J., Mischel P.S., Shaw R.J. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 2013, 23:143-158.
42. Sheen J.H., Zoncu R., Kim D., Sabatini D.M. Defective regulation of autophagy upon leucine deprivation reveals a targetable liability of human melanoma cells in vitro and in vivo. Cancer Cell 2011, 19:613-628.
43. Stewart S.A., Dykxhoorn D.M., Palliser D., Mizuno H., Yu E.Y., An D.S., Sabatini D.M., Chen I.S., Hahn W.C., Sharp P.A., et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 2003, 9:493-501.
44. Sui X., Chen R., Wang Z., Huang Z., Kong N., Zhang M., Han W., Lou F., Yang J., Zhang Q., et al. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis. 2013, 4:e838.
45. Takeuchi H., Kondo Y., Fujiwara K., Kanzawa T., Aoki H., Mills G.B., Kondo S. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res. 2005, 65:3336-3346.
46. Tamburini J., Green A.S., Bardet V., Chapuis N., Park S., Willems L., Uzunov M., Ifrah N., Dreyfus F., Lacombe C., et al. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood 2009, 114:1618-1627.
47. van Galen P., Kreso A., Mbong N., Kent D.G., Fitzmaurice T., Chambers J.E., Xie S., Laurenti E., Hermans K., Eppert K., et al. The unfolded protein response governs integrity of the haematopoietic stem-cell pool during stress. Nature 2014, 510:268-272.
48. Vázquez C.L., Colombo M.I. Assays to assess autophagy induction and fusion of autophagic vacuoles with a degradative compartment, using monodansylcadaverine (MDC) and DQ-BSA. Methods Enzymol. 2009, 452:85-95.
49. Wang Q., Mora-Jensen H., Weniger M.A., Perez-Galan P., Wolford C., Hai T., Ron D., Chen W., Trenkle W., Wiestner A., Ye Y. ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proc. Natl. Acad. Sci. USA 2009, 106:2200-2205.
50. Wiederschain D., Wee S., Chen L., Loo A., Yang G., Huang A., Chen Y., Caponigro G., Yao Y.M., Lengauer C., et al. Single-vector inducible lentiviral RNAi system for oncology target validation. Cell Cycle 2009, 8:498-504.
51. Xiao B., Sanders M.J., Carmena D., Bright N.J., Haire L.F., Underwood E., Patel B.R., Heath R.B., Walker P.A., Hallen S., et al. Structural basis of AMPK regulation by small molecule activators. Nat. Commun. 2013, 4:3017.
52. Yeung J., Esposito M.T., Gandillet A., Zeisig B.B., Griessinger E., Bonnet D., So C.W. β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell 2010, 18:606-618.